PNA5

PNA5 is a novel, blood-brain barrier permeable glycosylated angiotensin- (1-7) peptide and MasR agonist. PNA5 inhibits IL-7, increases IL-10. PNA5 inhibits ROS generation, decreases Iba-1 expression. PNA5 exhibits sustained cognitive protective effects. PNA5 rescues blunted cerebral functional hyperemia. PNA5 can be used in the research of inflammation-related brain diseases[1].

Product Specifications

CAS Number

[2186644-51-7]

UNSPSC

12352005

Target

Interleukin Related; Reactive Oxygen Species (ROS)

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Field of Research

Neurological Disease; Inflammation/Immunology; Cardiovascular Disease

Smiles

OC(C=C1)=CC=C1C[C@H](NC([C@H](C(C)C)NC([C@H](CCCNC(N)=N)NC([C@@H](N)CC(O)=O)=O)=O)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@H](C(N[C@H](C(N)=O)CO[C@@H]2O[C@@H]([C@H]([C@@H]([C@H]2O)O)O)CO)=O)CC3=CN=CN3)=O)=O

Molecular Formula

C45H71N13O16

Molecular Weight

1050.12

References & Citations

[1]Hay M, et al. A Novel Angiotensin- (1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction. J Pharmacol Exp Ther. 2019 Apr;369 (1) :9-25.|[2]Hoyer-Kimura C, et al. PNA5, A Novel Mas Receptor Agonist, Improves Neurovascular and Blood-Brain-Barrier Function in a Mouse Model of Vascular Cognitive Impairment and Dementia. Aging Dis. 2024 Aug 1;15 (4) :1927-1951.